Effects of sub-anesthetic doses of esketamine on postoperative sleep disturbance and pain in patients undergoing lumbar interbody fusion—A randomized, double-blind, placebo-controlled, two-center trial
Authors' conclusion
Sub-anesthetic doses of esketamine can reduce the incidence of PSD on POD 1, reduce postoperative pain, and improve QoR.
Study context
- Population
- Patients undergoing lumbar interbody fusion, two hospitals in China
- Participants
- 80 patients
- Comparison
- Sub-anesthetic esketamine vs saline placebo
- Esketaminen = 40
- Placebon = 40reference
- Primary endpoint
- Incidence of postoperative sleep disturbance (PSD)
- Follow-up
- POD 1
Methodological detailsdouble-blind, placebo-controlled, two-center, Conducted June 6, 2024 to November 26, 2024
- Double-blind
- Placebo-controlled
- Two-center
- Conducted June 6, 2024 to November 26, 2024
Primary result
As reported in the abstract
P = 0.003
Further findings
| Outcome | Esketamine | Placebo | P value |
|---|---|---|---|
| VAS-pain at rest · 1, 3 and 6 h after surgery | P < 0.05 | ||
| VAS-pain with movement · 1, 3, 6 and 24 h after surgery | P < 0.05 | ||
| QoR-15 score · POD 1 | 107 (IQR 103–117) | 99 (IQR 96–108) | P = 0.005 |
| QoR-15 score · POD 3 | 130 (IQR 122–136) | 124 (IQR 117–127) | P = 0.003 |
Visual Analog Scale (VAS)-pain at rest · 1, 3 and 6 h after surgery
- Lower in the Esketamine group vs Placebo
VAS-pain with movement · 1, 3, 6 and 24 h after surgery
- Lower in the Esketamine group vs Placebo
Original publication
Effects of sub-anesthetic doses of esketamine on postoperative sleep disturbance and pain in patients undergoing lumbar interbody fusion—A randomized, double-blind, placebo-controlled, two-center trial. Anaesth Crit Care Pain Med. Published 14 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →